Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016', provides in depth analysis on TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted pipeline therapeutics. The report provides comprehensive information on the TAR DNA Binding Protein 43 (TDP43 or TARDBP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for TAR DNA Binding Protein 43 (TDP43 or TARDBP) - The report reviews TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics and enlists all their major and minor projects - The report assesses TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding TAR DNA Binding Protein 43 (TDP43 or TARDBP) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 TAR DNA Binding Protein 43 (TDP43 or TARDBP) Overview 6 Therapeutics Development 7 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Stage of Development 7 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Therapy Area 8 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Indication 9 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Companies 12 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Companies Involved in Therapeutics Development 19 Biogen Inc 19 ImStar Therapeutics Inc. 20 Primary Peptides, Inc. 21 SK Biopharmaceuticals Co Ltd 22 TauRx Therapeutics Ltd 23 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Drug Profiles 24 IMS-088 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 NI-205 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 TRx-0237 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Dormant Projects 34 TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Featured News & Press Releases 35 Sep 04, 2016: TRx-237-007 Phase 3 Clinical Trial Update 35 Jul 27, 2016: TauRx Reports First Phase 3 Results for LMTX 35 Jul 22, 2016: TauRx Phase 3 Trial TRx-237-007 in behavioural variant frontotemporal dementia 37 Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS 37 Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease 38 Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy 39 Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease 40 Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer's Disease 42 Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia 43 Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments 43 Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th 44 Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease 44 Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States 45 Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS 45 Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer's Disease at annual psychogeriatric conference in Korea 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Biogen Inc, H2 2016 19 Pipeline by ImStar Therapeutics Inc., H2 2016 20 Pipeline by Primary Peptides, Inc., H2 2016 21 Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 22 Pipeline by TauRx Therapeutics Ltd, H2 2016 23 Dormant Projects, H2 2016 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
